Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insight+_Senior Editor
Insights+: The US FDA New Drug Approvals in September 2020
The US FDA has approved 6 NDAs in Sept 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 85 novel products so far in 2020, including 6 in Sept 2020. Additionally, last year…
October 15, 2020
Insight+_Senior Editor
Insights+ Key Biosimilars Events of September 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…
October 1, 2020
Insights+: The US FDA New Drug Approvals in August 2020
Insights+: The US FDA New Drug Approvals in August 2020
The US FDA has approved multiple NDAs and BLAs in Aug 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 69 novel products so far in 2020, including 10 in Aug 2020. Additionally,…
September 17, 2020
Insights+ Key Biosimilars Events of August 2020
Insights+ Key Biosimilars Events of August 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Mylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…
September 3, 2020
Insights+: The US FDA New Drug Approvals in July 2020
Insights+: The US FDA New Drug Approvals in July 2020
The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…
August 27, 2020
Insights+ Key Biosimilars Events of July 2020
Insights+ Key Biosimilars Events of July 2020
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Cadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar) Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 2020 1. Samsung…
August 7, 2020
Insights+: COVID-19 Healthcare News Monthly Updates - July 2020
Insights+: COVID-19 Healthcare News Monthly Updates – July 2020
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019  PharmaShots is keeping a track of all of the important updates in the Life-sciences sector, where…
July 31, 2020
Insights+: The US FDA New Drug Approvals in June 2020
Insights+: The US FDA New Drug Approvals in June 2020
The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…
July 24, 2020
PharmaShots' Key Highlights of Second Quarter 2020
PharmaShots’ Key Highlights of Second Quarter 2020
The second quarter of 2020 has ended with big approvals in pharma and biotech industry. Moving with the latest approval of Roche's Phesgo and Enspryng & Zogenix's Fintepla. Highlights of the quarter is COVID-19 as the development of vaccines and drugs were on peak. Celltrion evaluated Remsima (biosimilar, infliximab) against COVID-19 in the UK. The…
July 7, 2020
Load more